Canadian Journal of Cardiology最新文献

Sirolimus-coated balloons in the Metal-Free registry: Favorable outcomes, unaddressed contemporary standards. 西罗莫司涂层气球在无金属登记：有利的结果，未解决的当代标准。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.035

Artur Dziewierz, Wojciech Wańha, Tomasz Rakowski

引用次数: 0

Signal Without Certainty: Prophylactic Surgical Left Atrial Appendage Exclusion in Sinus Rhythm. 信号不确定：窦性心律患者预防性手术左心耳排除。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.036

Jeffrey H Shuhaiber

引用次数: 0

Outcomes of Prasugrel versus Ticagrelor Following Percutaneous Coronary Intervention for Coronary Artery Disease. 经皮冠状动脉介入治疗冠心病后普拉格雷与替格瑞的疗效比较

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.033

Hritvik Jain, Nandan Patel, Jyoti Jain, Akshat Banga, Siddharth P Agrawal, Andrew M Goldsweig, Ann Gage, Alexander G Truesdell, J Dawn Abbott, Saraschandra Vallabhajosyula

引用次数: 0

Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment and Control: A Population-based Cohort Study. 2025年加拿大高血压指南关于高血压患病率、治疗和控制的流行病学意义：一项基于人群的队列研究

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.034

Victoria Ivensky, Gregory L Hundemer, Alexander A Leung, Ross T Tsuyuki, Rémi Goupil

{"title":"Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment and Control: A Population-based Cohort Study.","authors":"Victoria Ivensky, Gregory L Hundemer, Alexander A Leung, Ross T Tsuyuki, Rémi Goupil","doi":"10.1016/j.cjca.2026.04.034","DOIUrl":"https://doi.org/10.1016/j.cjca.2026.04.034","url":null,"abstract":"<p><strong>Background: </strong>In 2025, Hypertension Canada published a new guideline for the management of hypertension in primary care. Key changes included the adoption of lower blood pressure (BP) thresholds for hypertension diagnosis, treatment initiation, and treatment target. This study sought to evaluate the potential epidemiological impacts of the 2025 Hypertension Canada guideline and its implications for Canadian adults.</p><p><strong>Methods: </strong>Using data from the population-based CARTaGENE cohort, we compared how transitioning from the 2020 to the 2025 Hypertension Canada guideline recommendations could impact hypertension prevalence, indications for antihypertensive treatment, and BP control rates.</p><p><strong>Results: </strong>16,825 participants were included in the study. Implementation of the 2025 Hypertension Canada guideline increased the number of individuals with hypertension from 7,005 (41.6%) to 8,564 (50.9%, 95% CI, 50.2 to 51.6%), primarily affecting younger participants and those at low-to-moderate cardiovascular risk. For these individuals, initial non-pharmacological management focused on lifestyle optimization would be recommended. The need for antihypertensive treatment initiation increased by only 1.3% (95% CI 0.3 to 2.4%) and predominantly concerned individuals at high cardiovascular risk. Among treated participants, BP control rates decreased by 8.7% in the low-to-moderate risk group and increased by 9.9% in the high-risk group.</p><p><strong>Conclusion: </strong>Adoption of the 2025 Hypertension Canada guideline will substantially increase the prevalence of hypertension among 40-69 year-old Canadians. Non-pharmacological interventions are recommended for all individuals; however, new antihypertensive pharmacotherapy would be recommended for only a small subset, largely limited to those at high cardiovascular risk.</p>","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Translating Phenotype-Driven Pulmonary Embolism Care to the Bedside: Logistical Realities and Unmeasured Confounders. 翻译表型驱动的肺栓塞护理到床边：后勤现实和未测量的混杂因素。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-04 DOI: 10.1016/j.cjca.2026.04.031

Jakub Stępniewski, Grzegorz Kopeć

引用次数: 0

Toward Foundation Models in Cardiology. 迈向心脏病学基础模型。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-02 DOI: 10.1016/j.cjca.2026.04.030

Dor Hadida Barzilai, Alon Gorenshtein, Yiftach Barash, Mahmud Omar, Daor Hayu, Eyal Klang

引用次数: 0

Outcome Monitoring and Intermediate End Points for Gene Therapy 基因治疗的结局监测和中间终点。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-01 Epub Date: 2025-12-02 DOI: 10.1016/j.cjca.2025.11.042

Deni Kukavica MD, PhD , Alessandro Trancuccio MD, PhD , Gabriel Brooks MD , Silvia G. Priori MD, PhD

{"title":"Outcome Monitoring and Intermediate End Points for Gene Therapy","authors":"Deni Kukavica MD, PhD , Alessandro Trancuccio MD, PhD , Gabriel Brooks MD , Silvia G. Priori MD, PhD","doi":"10.1016/j.cjca.2025.11.042","DOIUrl":"10.1016/j.cjca.2025.11.042","url":null,"abstract":"<div><div>Gene therapy, a technique that seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use, has evolved significantly. The design of gene therapy clinical trials, and in particular outcome monitoring and end point design, is of paramount clinical, scientific, and regulatory relevance, with practical, ethical, and financial implications for health care systems and society at large. Gene therapies are potentially irreversible, which demands that principal effects of the drug on the disease pathophysiology as well as clinical meaningfulness of the therapy, via end point specification, is well defined and measured reliably. Considering that gene therapy trials typically target rare disease and/or are resource-intensive, the sample sizes are limited, which creates a unique set of challenges. This further demands careful selection in the choice of the appropriate and feasible end points, best determined through multidisciplinary discussions that take into consideration the most appropriate statistical approach for the data analysis. In this review, we discuss the framework necessary for rational and robust outcome monitoring for gene therapy trials, and we review the currently used end points for gene therapy trials.</div></div>","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":"42 5","pages":"Pages 949-966"},"PeriodicalIF":5.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Primer on Cardiovascular Gene Therapy for the Practitioner: What Clinicians Need to Know 对从业者心血管基因治疗的入门：什么临床医生需要知道。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-01 Epub Date: 2025-12-01 DOI: 10.1016/j.cjca.2025.11.034

Cindy S. Argueta Portillo BS , Andrew P. Landstrom MD, PhD

引用次数: 0

Gene Replacement Therapy in Patients With Cardiac Disease: Challenges in Trial Design and Management of Adverse Events 心脏疾病的基因替代疗法：试验设计和不良事件管理的挑战。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-01 Epub Date: 2025-08-26 DOI: 10.1016/j.cjca.2025.08.340

Niccolò Maurizi MD , Kimberly N. Hong MD , Elizabeth Silver MD , Umang Patel BS , Eric D. Adler MD

{"title":"Gene Replacement Therapy in Patients With Cardiac Disease: Challenges in Trial Design and Management of Adverse Events","authors":"Niccolò Maurizi MD , Kimberly N. Hong MD , Elizabeth Silver MD , Umang Patel BS , Eric D. Adler MD","doi":"10.1016/j.cjca.2025.08.340","DOIUrl":"10.1016/j.cjca.2025.08.340","url":null,"abstract":"<div><div>Gene replacement therapy has emerged as a promising strategy to address the underlying molecular defects in inherited and acquired cardiomyopathies, shifting treatment from symptom palliation to potentially disease-modifying interventions. Most clinical programs use adeno-associated viral vectors to deliver functional DNAs, demonstrating safety, durable myocardial transduction, and early improvements in biomarkers or imaging end points. However, the rarity and heterogeneity of target populations constrain trial size and duration, making traditional morbidity and mortality outcomes infeasible. Central to overcoming these challenges has been the concurrent establishment of rigourous natural history cohorts. They serve as external controls, allowing for the capture of exact disease trajectories to define the optimal effective therapeutic windows. Natural history studies are critical to identifying clinically meaningful surrogate end points, ranging from circulating biomarkers and quantitative imaging measures to composite functional ranks that integrate exercise capacity with patient-reported symptoms. Collaborating with regulatory authorities to identify composite outcomes that combine surrogate outcomes predictive of morbidity and mortality with innovative patient-reported outcomes, the obstacles of statistical power and hard outcomes can be overcome. Last, a comprehensive understanding of the immune response to viral capsids, together with optimized and validated immunosuppressive regimens, is much needed to deliver durable, disease-modifying therapies to patients with genetic cardiac diseases. Continued collaboration among investigators, regulators, and patient communities, including rigourous natural history study design, surrogate qualification, and innovative trial frameworks, will be essential to realize the full potential of gene replacement therapies in cardiology.</div></div>","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":"42 5","pages":"Pages 933-948"},"PeriodicalIF":5.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Approaches to Cardiac Gene Therapy Delivery 心脏基因治疗递送的新方法。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-01 Epub Date: 2026-02-27 DOI: 10.1016/j.cjca.2026.02.031

Samta Veera MS, Ni-Hsuan Lin BS, Spyros A. Mavropoulos MD, PhD, Kiyotake Ishikawa MD, PhD

引用次数: 0